Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,651 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed Phase 4 Interventional Results available

A Comparison of Long-acting Injectable Medications for Schizophrenia

NCT01136772
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
haloperidol decanoate, paliperidone palmitate
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
22
States / cities
Palo Alto, California • New Haven, Connecticut • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study

NCT01804257
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Digital Health Feedback System
Other
Lead sponsor
Proteus Digital Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Not applicable Interventional

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

NCT01420575
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Visual Decision Aid and Shared Decision Making Model, Usual Care
Behavioral
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional

STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.

NCT02069925
View directory record Official record
Conditions
Psychosis, Schizophrenia
Interventions
Early Detection (ED), Usual Detection
Behavioral
Lead sponsor
Yale University
Other
Eligibility
16 Years to 35 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 14, 2026, 9:03 AM EDT
Completed No phase listed Observational

Game-based Telehealth Therapeutic Intervention in First Onset Psychosis

NCT04799717
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia Spectrum Disorders
Interventions
Gaming session
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 18 Years
Enrollment
8 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

The Use of Skills Training to Augment Compensated Work Therapy (CWT)/VI for Veterans With SMI

NCT00272168
View directory record Official record
Conditions
Mental Illness, Schizophrenia
Interventions
Maryland Program for Vocational Effectiveness, Supportive Treatment for SMI
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2016 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

NCT01646840
View directory record Official record
Conditions
Healthy
Interventions
PF-04958242 capsule, PF-04958242 oral solution
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 4 Interventional

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

NCT00169091
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Haloperidol
Drug
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 14, 2026, 9:03 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

NCT05890768
View directory record Official record
Conditions
Psychosis
Interventions
Lumateperone, Risperidone
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole for Bipolar Disorder and Alcohol Use Disorder

NCT02918370
View directory record Official record
Conditions
Bipolar Disorder, Alcoholism, Alcohol Abuse
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752
View directory record Official record
Conditions
Schizophrenia, Cognition, Psychosis
Interventions
Curcumin, Placebo
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Video Consent Versus Routine Consent for Participation in Research Studies

NCT00430391
View directory record Official record
Conditions
Schizophrenia
Interventions
DVD Consent, Routine Control
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Valproate in Late Life Schizophrenia

NCT00194025
View directory record Official record
Conditions
Schizophrenia
Interventions
Valproate
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations

NCT03485131
View directory record Official record
Conditions
Auditory Hallucination, Schizophrenia
Interventions
Transcranial direct-current stimulation (tDCS), Placebo
Device
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

NCT00206102
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine fumarate, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
63
States / cities
Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Thermoregulation Among Individuals With First-episode Psychosis

NCT04369677
View directory record Official record
Conditions
Psychosis, First Episode Psychosis
Interventions
Not listed
Lead sponsor
Nicholas Breitborde
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Rehabilitative Training for Older People With Schizophrenia

NCT00071591
View directory record Official record
Conditions
Schizophrenia
Interventions
Functional Adaptation Skills Training (FAST)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00705783
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot, Placebo depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
43
States / cities
Chandler, Arizona • Anaheim, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Improving Hallucinations by Targeting the rSTS With tES

NCT05165654
View directory record Official record
Conditions
Hallucinations, Auditory, Psychosis
Interventions
Transcranial Electrical Stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 1 Interventional

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

NCT01568203
View directory record Official record
Conditions
Schizophrenia
Interventions
AMG 579, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Trial of Treatment for Internalized Stigma in Schizophrenia

NCT02421237
View directory record Official record
Conditions
Schizophrenia
Interventions
Narrative Enhancement and Cognitive Therapy, Supportive Group Therapy
Behavioral
Lead sponsor
John Jay College of Criminal Justice, City University of New York
Other
Eligibility
21 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

NCT02477020
View directory record Official record
Conditions
Schizophrenia
Interventions
TAK-063 20 mg, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Springdale, Alaska • Culver City, California • Lemon Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis

NCT01196286
View directory record Official record
Conditions
Recent-Onset Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features, Psychotic Disorder Not Otherwise Specified (NOS)
Interventions
Multifamily Group Psychoeducation (MFG), Cognitive Remediation (CR)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 14, 2026, 9:03 AM EDT